Published in Clin Exp Immunol on February 01, 2003
Bladder Cancer Immunotherapy: BCG and Beyond. Adv Urol (2012) 1.27
TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther (2009) 1.13
Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol (2004) 1.04
Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer (2004) 1.04
The tuberculin skin test (TST) is affected by recent BCG vaccination but not by exposure to non-tuberculosis mycobacteria (NTM) during early life. PLoS One (2010) 1.00
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG). BMC Immunol (2007) 0.99
Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. Clin Exp Immunol (2010) 0.92
Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol (2007) 0.92
Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. Br J Cancer (2003) 0.91
Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res (2008) 0.89
Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol (2010) 0.87
Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells. Clin Exp Immunol (2007) 0.86
Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol (2011) 0.84
Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity. Clin Exp Immunol (2014) 0.84
Blocking IL-10 enhances bacillus Calmette-Guérin induced T helper Type 1 immune responses and anti-bladder cancer immunity. Oncoimmunology (2012) 0.78
Immunotherapeutic strategies for bladder cancer. Hum Vaccin Immunother (2014) 0.77
Prediction of response to bacillus Calmette-Guérin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio. Exp Ther Med (2012) 0.77
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
New use of BCG for recombinant vaccines. Nature (1991) 14.40
Differential effects of cytolytic T cell subsets on intracellular infection. Science (1997) 3.39
Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of Mycobacterium avium infection. Infect Immun (1994) 2.52
Immune response to Mycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol (1995) 2.48
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med (1991) 2.07
Helicobacter hepaticus-induced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation. Infect Immun (2001) 1.99
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66
Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res (1999) 1.61
Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol (2000) 1.57
Estrogen treatment down-regulates TNF-alpha production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J Immunol (2001) 1.48
Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst (1972) 1.48
Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol (1996) 1.46
Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun (1994) 1.39
Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol (1992) 1.38
Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am (1992) 1.33
Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol (1987) 1.33
T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol (1993) 1.24
Regulation of contact hypersensitivity by interleukin 10. J Exp Med (1994) 1.23
Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol (1990) 1.20
Expression of the nerve growth factor-regulated NGFI-A and NGFI-B genes in the developing rat. Development (1990) 1.20
Ultrastructural studies of histiocyte-tumor cell interactions during tumor regression after intralesional injection of Mycobacterium bovis. Cancer Res (1973) 1.16
Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol (1995) 1.14
Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol (1996) 1.14
Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer (2000) 1.12
Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP. J Biol Chem (1999) 1.08
Role of the immune response in BCG for bladder cancer. Eur Urol (1992) 1.07
Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res (1991) 1.06
T-helper 1-like subset selection in Mycobacterium bovis bacillus Calmette-Guérin-infected resistant and susceptible mice. Immunology (1994) 1.05
Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin. Cancer Res (1984) 0.96
Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management. J Urol (1987) 0.95
Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol (1986) 0.94
Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother (1993) 0.92
Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol (1997) 0.92
Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res (1992) 0.91
Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J Urol (1988) 0.90
Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol (1993) 0.90
Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guerin. Urol Res (1989) 0.89
Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. Urology (1991) 0.87
Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J Urol (1986) 0.87
Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J Urol (1986) 0.86
Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol (1990) 0.85
Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience. Eur Urol (2000) 0.85
Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol Immunother (1996) 0.85
Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis. Int J Cancer (1998) 0.83
Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: lack of a role of natural killer cells. Clin Immunol Immunopathol (1986) 0.83
Bacillus Calmette-Guérin (BCG): mechanism of action in superficial bladder cancer. Urology (1991) 0.81
Immune responses in mice after gastric and subcutaneous immunization with BCG. Scand J Immunol (1997) 0.80
Characterization of fibronectin attachment by a human transitional cell carcinoma line, T24. J Urol (1991) 0.80
Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. World J Urol (1993) 0.79
In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2). J Urol (1990) 0.78
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med (1991) 6.94
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A (2006) 6.33
Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem (2000) 4.24
Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med (2001) 3.96
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature (1994) 3.87
Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem (1998) 3.83
Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA (1993) 3.46
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature (1994) 3.46
Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG. Infect Immun (1988) 3.35
Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol (1994) 3.17
Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke (1996) 3.16
Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest (2001) 2.90
GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell (1996) 2.86
Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell (1992) 2.77
A randomized trial on root caries prevention in elders. J Dent Res (2010) 2.74
Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA (1995) 2.63
Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res (1996) 2.60
Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nat Med (1998) 2.56
The secreted antigens of Mycobacterium tuberculosis and their relationship to those recognized by the available antibodies. J Gen Microbiol (1988) 2.38
BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38
A microsatellite genetic linkage map of human chromosome 18. Genomics (1993) 2.35
A possible vulnerability locus for bipolar affective disorder on chromosome 21q22.3. Nat Genet (1994) 2.30
Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J (1997) 2.28
A comparison of active compression-decompression cardiopulmonary resuscitation with standard cardiopulmonary resuscitation for cardiac arrests occurring in the hospital. N Engl J Med (1993) 2.19
Chemical mapping of a single molecule by plasmon-enhanced Raman scattering. Nature (2013) 2.19
Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke (2001) 2.16
A solid-state amorphous selenium avalanche technology for low photon flux imaging applications. Med Phys (2010) 2.13
Pathology and probability. Likelihood ratios and receiver operating characteristic curves in the interpretation of bronchial brush specimens. Am J Clin Pathol (1995) 2.07
Chronic oxidative stress and radiation-induced late normal tissue injury: a review. Int J Radiat Biol (2004) 2.06
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol (1995) 2.05
Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene (2007) 2.03
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol (1995) 1.94
Sequence-specific DNA cleavage by Fe2+-mediated fenton reactions has possible biological implications. J Biol Chem (1999) 1.93
Identification of RIP3, a RIP-like kinase that activates apoptosis and NFkappaB. Curr Biol (1999) 1.85
The B-cell-specific transcription coactivator OCA-B/OBF-1/Bob-1 is essential for normal production of immunoglobulin isotypes. Nature (1996) 1.84
Bladder injection of "naked" hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. Am J Physiol Regul Integr Comp Physiol (2001) 1.83
Chemical constituents from Dendrobium densiflorum. Phytochemistry (2001) 1.82
Molecular basis for the explanation of the exponential growth of polyelectrolyte multilayers. Proc Natl Acad Sci U S A (2002) 1.80
A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10. Nat Genet (1993) 1.79
The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol (2001) 1.78
Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat (2011) 1.77
Medical complications in long-term survivors with X-linked myotubular myopathy. J Pediatr (1999) 1.74
Purified human factor activates heat shock promoter in a HeLa cell-free transcription system. J Biol Chem (1988) 1.74
Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int (1995) 1.74
Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation (2000) 1.70
Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke (1998) 1.69
Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer (2011) 1.69
Dominant effector genetics in mammalian cells. Nat Genet (2001) 1.68
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res (1998) 1.68
Three novel proteins of the syntaxin/SNAP-25 family. J Biol Chem (1998) 1.67
Wherefore art thou guanylin? Gastroenterology (1995) 1.66
Detection of programmed cell death using fluorescence energy transfer. Nucleic Acids Res (1998) 1.65
Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol Cell Biol (1994) 1.64
Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer (2004) 1.61
The palpable breast nodule. A cost-effectiveness analysis of alternate diagnostic approaches. Cancer (1993) 1.61
Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice. J Immunol (1999) 1.61
Urinary system. Cancer (1995) 1.58
Two high-resolution crystal structures of the recombinant N-lobe of human transferrin reveal a structural change implicated in iron release. Biochemistry (1998) 1.57
Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut (2007) 1.57
Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun (1998) 1.57
The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia (1995) 1.55
MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene (2011) 1.54
The structure of human pancreatic alpha-amylase at 1.8 A resolution and comparisons with related enzymes. Protein Sci (1995) 1.54
Identification of a new mouse beta-chemokine, thymus-derived chemotactic agent 4, with activity on T lymphocytes and mesangial cells. J Immunol (1997) 1.53
Development of a mouse model for nonbacterial prostatitis. J Urol (1994) 1.53
Enhanced apoptotic response to photodynamic therapy after bcl-2 transfection. Cancer Res (1999) 1.52
Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst (1997) 1.52
Expression of CD44 isoforms in human prostate tumor cell lines. Prostate (1996) 1.52
Earthquake in a maze: compressional rupture branching during the 2012 M(w) 8.6 Sumatra earthquake. Science (2012) 1.52
Seismic images of crust and upper mantle beneath Tibet: evidence for Eurasian plate subduction. Science (2002) 1.52
Bone marrow stromal cells regulate caspase 3 activity in leukemic cells during chemotherapy. Leuk Res (2001) 1.51
ART and conventional root restorations in elders after 12 months. J Dent Res (2006) 1.50
TNIK, a novel member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton. J Biol Chem (1999) 1.50
Minimum length of sequence homology required for in vivo cloning by homologous recombination in yeast. Plasmid (1997) 1.49
Ancillary methods for the detection of recurrent urothelial neoplasia. Cancer (2000) 1.49
Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. J Immunol (1997) 1.48
Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun (2001) 1.47
A Mycobacterium leprae gene encoding a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells. Infect Immun (1995) 1.46
Photodynamic therapy: a mitochondrial inducer of apoptosis. Cell Death Differ (1999) 1.46
Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J Immunol (2000) 1.45
Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol (2000) 1.45
A specialized pathway affecting virulence glycoconjugates of Leishmania. Science (1995) 1.45
Value of having a cytopathologist present during percutaneous fine-needle aspiration biopsy of lung: report of 55 cancer patients and metaanalysis of the literature. AJR Am J Roentgenol (1993) 1.45
Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol (1996) 1.45
Signet-ring cell carcinoma of the prostate. Arch Pathol Lab Med (1992) 1.44
Technology assessment in anatomic pathology. An illustration of test evaluation using fine-needle aspiration biopsy. Arch Pathol Lab Med (1994) 1.44
The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol (1997) 1.43
The nonsense-mediated decay pathway and mutually exclusive expression of alternatively spliced FGFR2IIIb and -IIIc mRNAs. J Biol Chem (2000) 1.42
Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest (1990) 1.42
Change in paternity and select perinatal outcomes: causal or confounded? J Obstet Gynaecol (2012) 1.42
Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol (2006) 1.42
Field reversed configuration confinement enhancement through edge biasing and neutral beam injection. Phys Rev Lett (2012) 1.41
p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues. Oncogene (2001) 1.41